A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ARC-20)
ARC-20
Phase 1 other active
Quick answer
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) for Solid Tumors, Clear Cell Renal Cell Carcinoma is a Phase 1 program (other) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arcus Biosciences
- Indication
- Solid Tumors, Clear Cell Renal Cell Carcinoma
- Phase
- Phase 1
- Modality
- other
- Status
- active